Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma

Abstract

Glioblastoma (GBM), the most common primary brain tumor in adults, is characterized by low survival rates and a grim prognosis. Current treatment modalities, including extensive surgical resection, chemotherapy, and radiation therapy, often yield limited success due to the brain’s sensitivity, leading to significant side effects. Exciting advancements in immunotherapy have recently shown promise in treating various types of tumors, raising hopes for improved outcomes in brain tumor patients. One promising immunotherapy approach is chimeric antigen receptor (CAR) T-cell therapy, which recognizes surface proteins on targeted tumor cells and redirects cytotoxicity towards specific targets. This review aims to discuss the existing research and future prospects for CAR T-cell immunotherapy in treating glioblastoma.

Combination of tumor antigen drainage and immune activation to promote a cancer-immunity cycle against glioblastoma

“…For example, in a recent randomized phase III clinical trial focusing on programmed cell death pathway inhibition in GBM, the anti-PD-1 therapy failed to prolong overall survival in these patients [6]. Similarly, initial tumor regression noted in a clinical trial adoptive T cell transfer for GBM was subsequently followed by disease progression [7]. Despite these negative results, several studies showed that some patient subsets exhibit prolonged survival following this form of ICB [8,9].…”